http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-106362165-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-005 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10 |
| filingDate | 2016-11-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2019-12-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2019-12-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-106362165-B |
| titleOfInvention | Function and application of ubiquitin-specific protease 18 in treating fatty liver and type II diabetes |
| abstract | The invention discloses a function and application of a USP18 gene in fatty and liver diabetes. The results of inducing an obese mouse model by high fat diet with USP18 knockout mice and wild type C57 mice as experimental subjects show that USP18-KO mice exhibit obesity and have fasting blood glucose levels higher than those of the control group WT mice compared with wild type C57 mice. The tolerance of USP18-KO mice to glucose is obviously weakened by an intraperitoneal glucose tolerance test. Results of liver weight, liver/body weight ratio and lipid components and the like show that USP18-KO mice on high-fat diet have obviously serious fatty liver lesion and obviously increased lipid accumulation. Therefore, USP18 can be used as a drug target for screening and treating fatty liver and/or type II diabetes, and the accelerant can be used for preparing drugs for treating fatty liver and/or type II diabetes. |
| priorityDate | 2016-11-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 111.